PrEP Impact Trial
Research type
Research Study
Full title
PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation
IRAS ID
228166
Contact name
Damon Foster
Contact email
Sponsor organisation
Chelsea and Westminster Hospital NHS Foundation Trust
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
HIV pre-exposure prophylaxis (PrEP) is the use of anti-HIV medicines by HIV negative people in order to prevent them from becoming HIV positive if exposed to HIV.
Currently, the combination drug containing tenofovir and emtricitabine is licensed in Europe for use as HIV PrEP. We know from previous studies worldwide that this combination drug is very good at reducing the risk of HIV infection and several countries have implemented PrEP programmes to provide PrEP to individuals at high risk of HIV.
However, it is difficult to effectively plan for a national PrEP programme in England without knowing how many people will need PrEP, how many will want to take PrEP, and how long they will stay on PrEP.
In order to find this out, the PrEP Impact Trial will make PrEP available to 10,000 people over three years. HIV negative men and women attending sexual health clinics in England will have their risk of HIV assessed by their care team and be offered PrEP if they meet the eligibility criteria. Through the trial we will be able to measure how many attendees at sexual health clinics meet eligibility criteria for PrEP, how many of these take up the offer of PrEP and how long they remain on PrEP for.
There will not be any additional tests other than those recommended for the safe delivery of PrEP. These include tests for sexually transmitted infections (STIs), hepatitis and HIV as well as urine and blood tests to monitor kidney function. Information about attendances and test results will be anonymously collected through the existing data reporting system that sexual health clinics currently use to report to Public Health England.
REC name
London - Hampstead Research Ethics Committee
REC reference
17/LO/1134
Date of REC Opinion
3 Aug 2017
REC opinion
Further Information Favourable Opinion